Publications by authors named "Vanvoorden V"
Article Synopsis
- Bimekizumab, a monoclonal antibody targeting interleukin-17A/F, shows better results than secukinumab in treating psoriasis over one year.
- The BE RADIANT trial evaluated its safety and efficacy for 2 years, with participants receiving either bimekizumab or secukinumab followed by an open-label extension of bimekizumab.
- Results indicated higher complete skin clearance rates with bimekizumab at Week 48 (74.8% vs 52.8%), and these effects were maintained or improved by Week 96; side effects included nasopharyngitis and urinary tract infections.
Article Synopsis
- The study evaluates the long-term effectiveness of bimekizumab (BKZ) for treating moderate-to-severe plaque psoriasis over three years, particularly focusing on maintaining the results achieved at Week 16.
- Data from multiple phase III studies and an ongoing open-label extension were used, showing a significant number of patients maintaining high levels of improvement in their psoriasis symptoms throughout the three-year period.
- Overall, the results indicate that most patients who responded positively at Week 16 continued to experience substantial benefits and improvements in their quality of life due to ongoing BKZ treatment.
Article Synopsis
- Discontinuation of biologic treatments in psoriasis is often due to ineffectiveness or side effects, leading to clinicians and patients considering switching therapies.
- The study evaluates the effectiveness and safety of switching to bimekizumab from three other biologics (adalimumab, ustekinumab, and secukinumab) over a period of up to 80 weeks.
- Results showed significant improvements in symptoms and quality of life for most patients who switched to bimekizumab, with a high percentage achieving substantial reductions in psoriasis severity, especially among those who initially did not respond well to their previous treatments.
Article Synopsis
- 1-year data showed bimekizumab's effectiveness exceeds that of adalimumab for treating moderate-to-severe plaque psoriasis, with safe outcomes.
- The BE SURE trial tested bimekizumab over 56 weeks, leading into the BE BRIGHT open-label extension for more extended safety and efficacy evaluation.
- By week 104, high PASI 90 (91.2% and 89.7%) and PASI 100 (72.3% and 68.1%) responses were seen with bimekizumab, while adalimumab patients also improved significantly after switching to bimekizumab.
Article Synopsis
- Bimekizumab showed significant improvement in treating moderate-to-severe plaque psoriasis over 52 weeks in a phase 3 study, especially in the Japanese patient group.
- In the study, patients were assigned to receive either bimekizumab, ustekinumab, or a placebo, with bimekizumab showing superior results at week 16 according to key efficacy measures.
- The treatment was found to be well tolerated, with a safety profile consistent with the broader global results.
Article Synopsis
- Bimekizumab is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, and its effectiveness in treating moderate-to-severe plaque psoriasis compared to secukinumab (which targets only interleukin-17A) is unclear.
- In a phase 3b trial involving 743 patients, participants were assigned to receive either bimekizumab or secukinumab, and the main measure of success was a 100% reduction in the Psoriasis Area and Severity Index (PASI) score by week 16.
- Results showed that 61.7% of those on bimekizumab achieved PASI 100 by week 16,
Article Synopsis
- - Bimekizumab is a monoclonal antibody that targets interleukin-17A and interleukin-17F, and its effectiveness compared to adalimumab (a TNF inhibitor) in treating moderate-to-severe plaque psoriasis was investigated.
- - In a study involving 478 patients, those receiving bimekizumab saw significantly higher rates of improvement (86.2% achieving a 90% reduction in PASI score) compared to those on adalimumab (47.2%).
- - The results indicated that bimekizumab not only met noninferiority standards but also demonstrated superior efficacy, providing stronger evidence for its use in psoriasis treatment.
Article Synopsis
- A phase 3 trial called BE VIVID evaluated the efficacy and safety of bimekizumab, a monoclonal antibody targeting IL-17F and IL-17A, compared to placebo and ustekinumab for treating moderate to severe plaque psoriasis over a 52-week period.
- The trial involved randomizing adults with significant psoriasis symptoms across multiple countries and included a total treatment regimen that permitted some patients to switch to bimekizumab after 16 weeks.
- Primary outcomes focused on achieving at least a 90% improvement in psoriasis severity and a clear or almost clear rating on a global assessment at the 16-week mark.
Article Synopsis
- Bimekizumab, a monoclonal IgG1 antibody targeting IL-17F and IL-17A, was studied for its effectiveness and safety in treating moderate to severe plaque psoriasis over 56 weeks.
- The BE READY trial involved 435 participants across nine countries and compared bimekizumab with a placebo to assess treatment outcomes based on specific measurement scales.
- Results showed that 91% of patients on bimekizumab achieved significant skin improvement (PASI90) by week 16, highlighting its potential as an effective treatment for psoriasis.
Over the last decade, health related quality of life (HRQOL) investigations have become an increasingly important part of many cancer clinical trial research programs. This paper presents a review of all HRQOL studies published by the European Organisation for Research and Treatment of Cancer (EORTC), one of the largest clinical trials organisations in Europe. The findings highlight 24 clinical trials that have been published to date, enrolling over 9000 patients.
View Article and Find Full Text PDFManagement of skin reactions during radiotherapy: a study of nursing practice.
Eur J Cancer Care (Engl)
March 2005
The aim of this study was to investigate the consensus of skin care advice given by nurses during radiotherapy. Sixty-seven nurses, identified through nine Belgian radiotherapy departments, responded to a questionnaire survey consisting of 58 items regarding prevention and management of erythema, dry desquamation and moist desquamation. Consensus for a given advice was categorized as small if less than 50% of the nurses gave the same answer, as moderate if between 50% and 75% and as large when more than 75%.
View Article and Find Full Text PDFAlthough health-related quality of life (HRQOL) is increasingly reported as an important endpoint in cancer clinical trials, questions still remain about the quality of its reporting. The aim of this study was to evaluate the level of reporting of HRQOL in randomised controlled trials (RCTs) of colorectal cancer (CRC). A systematic literature search from 1980 to March 2003 was undertaken on a number of databases.
View Article and Find Full Text PDFPurpose: Non-small-cell lung cancer (NSCLC), a leading cause of cancer-related deaths in both developed and developing countries, heavily impacts patient health-related quality of life (HRQOL). Although recent research has found many positive and significant steps in randomized controlled trials (RCTs) in which HRQOL has been used as an outcome, questions remain regarding methodologic quality and impact value of HRQOL outcome assessments in some RCTs. To date, no detailed systematic review exists of HRQOL methodology in NSCLC RCTs.
View Article and Find Full Text PDFOver the last decade, Quality of Life (QOL) research has become an important aspect of cancer clinical trials. A dramatically increasing number of published studies, both randomised and non-randomised, report QOL outcomes. There is increasing evidence that QOL results impact on both future research and treatment decisions for clinicians.
View Article and Find Full Text PDF